Fujifilm Diosynth Announces Collaboration on a New 20,000-Liter Microbial Biologics Facility for Use by Its Contract Development and Manufacturing Customers

Fujifilm logo neu Diosynth Logo

Billingham, U.K.,   June 6, 2016 / B3C newswire / -- FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced that it is in the process of establishing a long-term collaboration with MSD, a global biopharmaceutical company known as Merck in the U.S. and Canada, to invest in and operate a large-scale microbial-biologics facility for supply of active pharmaceutical ingredient (API) to its customers.

This collaboration involves a $60-million USD investment by MSD at its Brinny manufacturing plant in Innishannon, County Cork, Ireland. MSD in Brinny has been in operation for more than 30 years and is an integrated site for the development, testing and manufacturing of biologics.

It is intended that the large-scale biologics operations at MSD in Brinny will be operational in early 2018 for biotech and pharma customers of Fujifilm Diosynth.

The collaboration:

  • Addresses a market need for large-scale microbial biologics manufacturing;
  • Complements Fujifilm Diosynth’s existing microbial capacity that ranges from 100L up to 5000L both in the USA and UK; and
  • Enables Fujifilm Diosynth’s customers to benefit from MSD’s strong track record with large-scale microbial operations.

Fujifilm Diosynth will lead customer interactions, program management and process and analytical development, and the MSD facility in Brinny will operate as cGMP manufacturing support for Fujifilm Diosynth’s CDMO business, enabling seamless technology transfer and technical support.

Microbial fermentation remains vital technology for the process of manufacturing biologics, and this investment, drawing on the latest production advances, will enable Fujifilm Diosynth’s existing and future customers to have a clear and secure line-of-sight to higher product volumes along with lower cost-of-goods. The latter is particularly important as products enter late clinical phase and commercialization.

Steve Bagshaw, CEO of Fujifilm Diosynth, said “We are delighted to progress this collaboration which illustrates how innovative approaches bridging pharma and CDMO can build value for suppliers and ultimately patients.”

Sanat Chattopadhyay, president of the MSD Manufacturing Division, said: “MSD is excited to collaborate with Fujifilm Diosynth through expanded capabilities in bulk microbial fermentation and downstream support services. This will allow MSD to use and further develop the skills and competencies of the people at the MSD site in Brinny and build on the site’s long tradition of manufacturing excellence.”

About Fujifilm
FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract Development and Manufacturing Organization with locations in Billingham, UK, RTP, North Carolina and College Station, Texas.  FUJIFILM Diosynth has over thirty  years of combined experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect cell line systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.  For more information, go to: www.fujifilmdiosynth.com

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies.  In the year ended March 31, 2016, the company had global revenues of $19.0 billion, at an exchange rate of 113 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com


Liza M. Rivera
Fujifilm Diosynth Biotechnologies
+1 919-325-6972
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.